Weight Gain and Antiretroviral Therapy

Overview

Journal Infect Dis Clin North Am

Specialty Infectious Diseases

Date 2024 Jun 13

PMID 38871568

Authors

Samuel S Bailin

John R Koethe

Affiliations

Soon will be listed here.

Abstract

Antiretroviral therapy (ART) agents as a determinant of body weight in ART-naïve and ART-experienced persons with human immunodeficiency virus (HIV) (PWH) has become a major focus area in research and clinical settings. Recent studies demonstrating weight-suppressing properties of efavirenz and tenofovir disoproxil fumarate led to re-evaluation of weight gain studies, and a reassessment of whether other agents are weight promoting versus weight neutral. In this review, the authors synthesize recent literature on factors related to obesity, clinical measurements of adiposity, weight gain in ART-naïve and ART-experienced PWH, metabolic consequences of ART and weight gain, and the clinical management of weight gain in PWH.

Citing Articles

Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection.

Truscello E, Wang S, Young J, Sebastiani G, Walmsley S, Hull M J Infect Dis. 2024; 231(1):e101-e112.

PMID: 39417816 PMC: 11793071. DOI: 10.1093/infdis/jiae487.

References

Graff M, Scott R, Justice A, Young K, Feitosa M, Barata L . Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults. PLoS Genet. 2017; 13(4):e1006528. PMC: 5407576. DOI: 10.1371/journal.pgen.1006528. View

Engelson E, Agin D, Kenya S, Werber-Zion G, Luty B, Albu J . Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006; 55(10):1327-36. DOI: 10.1016/j.metabol.2006.05.018. View

Koethe J, Lukusa A, Giganti M, Chi B, Nyirenda C, Limbada M . Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2009; 53(4):507-13. PMC: 3749827. DOI: 10.1097/QAI.0b013e3181b32baf. View

Becofsky K, Wing E, McCaffery J, Boudreau M, Wing R . A Randomized Controlled Trial of a Behavioral Weight Loss Program for Human Immunodeficiency Virus-Infected Patients. Clin Infect Dis. 2017; 65(1):154-157. PMC: 6433423. DOI: 10.1093/cid/cix238. View

Wilding J, Batterham R, Calanna S, Davies M, Van Gaal L, Lingvay I . Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11):989-1002. DOI: 10.1056/NEJMoa2032183. View

Deurenberg P, Yap M, van Staveren W . Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord. 1999; 22(12):1164-71. DOI: 10.1038/sj.ijo.0800741. View

Fabbrini E, Sullivan S, Klein S . Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2009; 51(2):679-89. PMC: 3575093. DOI: 10.1002/hep.23280. View

Zhang Y, Fowler K, Hamilton G, Cui J, Sy E, Balanay M . Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018; 91(1089):20170959. PMC: 6223150. DOI: 10.1259/bjr.20170959. View

Taramasso L, Berruti M, Briano F, Di Biagio A . The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. AIDS. 2020; 34(6):877-881. DOI: 10.1097/QAD.0000000000002496. View

10.

Surial B, Mugglin C, Calmy A, Cavassini M, Gunthard H, Stockle M . Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. Ann Intern Med. 2021; 174(6):758-767. DOI: 10.7326/M20-4853. View

11.

Nguyen Q, Wooten D, Lee D, Moreno M, Promer K, Rajagopal A . Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV. Clin Infect Dis. 2024; 79(4):978-982. DOI: 10.1093/cid/ciae151. View

12.

Milic J, Renzetti S, Ferrari D, Barbieri S, Menozzi M, Carli F . Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens. AIDS. 2022; 36(12):1643-1653. DOI: 10.1097/QAD.0000000000003289. View

13.

Esber A, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J . Weight gain during the dolutegravir transition in the African Cohort Study. J Int AIDS Soc. 2022; 25(4):e25899. PMC: 9008168. DOI: 10.1002/jia2.25899. View

14.

Macallan D, McNurlan M, Milne E, Calder A, Garlick P, Griffin G . Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr. 1995; 61(4):818-26. DOI: 10.1093/ajcn/61.4.818. View

15.

Nuttall F . Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2016; 50(3):117-128. PMC: 4890841. DOI: 10.1097/NT.0000000000000092. View

16.

Kerchberger A, Sheth A, Angert C, Mehta C, Summers N, Ofotokun I . Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. Clin Infect Dis. 2019; 71(3):593-600. PMC: 7384314. DOI: 10.1093/cid/ciz853. View

17.

Fan J, Brown B, Hanson H, Kowaleski-Jones L, Smith K, Zick C . Moderate to vigorous physical activity and weight outcomes: does every minute count?. Am J Health Promot. 2013; 28(1):41-9. PMC: 5512715. DOI: 10.4278/ajhp.120606-QUAL-286. View

18.

Achhra A, Sabin C, Ryom L, Hatleberg C, Antonella dAminio M, De Wit S . Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D: A: D Cohort Analysis. J Acquir Immune Defic Syndr. 2018; 78(5):579-588. DOI: 10.1097/QAI.0000000000001722. View

19.

Bhagwat P, Ofotokun I, McComsey G, Brown T, Moser C, Sugar C . Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. Antivir Ther. 2017; 22(7):577-586. PMC: 5610106. DOI: 10.3851/IMP3148. View

20.

Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M . CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2020; 73(11):e3902-e3909. PMC: 8653639. DOI: 10.1093/cid/ciaa1073. View